On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.

Investment will optimize access to quality diagnosis, increase private sector engagement, address the burden of latent tuberculosis infection (LTBI) and catalyse community action towards TB elimination.

The Global Coalition of TB Activists (GCTA) and FIND will host a webinar on advancements in TB diagnostics on 26 September 2019.

-- The Voices for Diagnosis annual prize is open to patient groups as well as health and rights advocacy organizations, acknowledging the key role of communities in promoting diagnostic access
-- In 2018/19, three awards of US$10,000 each – contributed by FIND; BD, Inc; and Johnson & Johnson – will be made to recognize and support initiatives that encourage appropriate antibiotic use and fight antimicrobial resistance
-- The prize will be adjudicated and supported by the Diagnostics Ambassadors, an informal network of thought leaders from diverse disciplines who help champion the important role played by diagnostics in global health

The World Health Organization (WHO) and FIND released a technical guide on sequencing, The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide.

29 November 2017: The End TB Strategy introduced by the World Health Organization (WHO) and adopted by the World Health Assembly aims to reduce TB related deaths by 95% and new TB infections by 90% by 2035. Approximately one quarter to one third of the world’s population is currently infected with the M. tuberculosis bacteria and the risk of developing an active form of the disease among infected individuals is between 5 and 15 percent.

The work plan template is intended to guide the implementation of Xpert MTB/RIF testing in facilities providing clinical services.

FIND is pleased to announce the finalization of a memorandum of understanding with the Research Institute of the McGill University Health Centre in Montreal, with a focus on tuberculosis (TB) diagnostics.

CAPE TOWN, South Africa and GENEVA and SUNNYVALE, Calif., Dec. 3, 2015 -- FIND and Cepheid today announced that they are broadening their collaboration on bringing point-of-care tuberculosis (TB) diagnosis to all levels of the health system in low and middle-income countries (LMICs). The work under the collaboration will focus on evaluating and implementing Cepheid's new GeneXpert® Omni system and Xpert® MTB/RIF Ultra test, in addition to assessing the system's cloud-based connectivity. These efforts will ultimately benefit all stakeholders, as the resulting data and know-how will be made publicly available.

A new report from FIND, McGill International TB Centre, and UNITAID, entitled “TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics”, notes that there is already a sizeable TB diagnostic market in these four countries.